Recent Updates
Recently added Catalysts

SCH 530348

Phase 2

Arterial Obstructive Diseases | Small molecule | Cardiovascular |Merck & Company, Inc.|Last Updated: May 25, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment1,030
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00132912Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)PHASE2 COMPLETED 1,030 — — Aug 30, 2005Jan 28, 2007May 25, 2017 - —
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Incidence of bleeding through the end of treatment in subjects undergoing percutaneous coronary intervention
Secondary Endpoints
Incidence of bleeding throughout treatment and follow-up
Incidence of death and major adverse cardiac events
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION
Interventions
NameTypeDescription
SCH 530348DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range45 Years — N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: * A person who is 45 years or older and is mentally competent to provide a signed written informed consent. * A person who is scheduled to undergo a percutaneous coronary intervention or a heart catheterization with the intent to undergo a percutaneous coronary intervention. * I...

Unlock Eligibility Criteria